Eyenovia Inc
NASDAQ:EYEN
Intrinsic Value
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. [ Read More ]
The intrinsic value of one EYEN stock under the Base Case scenario is 4.062 USD. Compared to the current market price of 0.986 USD, Eyenovia Inc is Undervalued by 76%.
Valuation Backtest
Eyenovia Inc
Run backtest to discover the historical profit from buying and selling EYEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Eyenovia Accelerates Commercial Strategy in Q4 2023
2023-Q4 Earnings Call
In the fourth quarter of 2023, Eyenovia advanced its commercial strategy with two FDA-approved products and two more in Phase III. The company highlighted its revenue growth strategies, including expanding its sales force and signing co-promotion agreements with NovaBay and Vision Source. They are also exploring a new opportunity in dry eye treatment, a market valued at over $3.6 billion. Eyenovia reported a net loss of $8 million for Q4 and $27.3 million for the year. They've generated $16 million in license fees to date and stand to earn an additional $25 million in milestones. With a focus on its Optejet technology, the company is positioned for growth, particularly as it makes strides in addressing pediatric myopia with MicroPine and expands its manufacturing capabilities.
Balance Sheet Decomposition
Eyenovia Inc
Current Assets | 20.7m |
Cash & Short-Term Investments | 14.8m |
Receivables | 624.5k |
Other Current Assets | 5.2m |
Non-Current Assets | 8.1m |
PP&E | 5m |
Intangibles | 2.1m |
Other Non-Current Assets | 908.6k |
Current Liabilities | 9.5m |
Accounts Payable | 1.8m |
Accrued Liabilities | 2.4m |
Other Current Liabilities | 5.4m |
Non-Current Liabilities | 10.2m |
Long-Term Debt | 9m |
Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Eyenovia Inc
Revenue
|
3.8k
USD
|
Operating Expenses
|
-25.4m
USD
|
Operating Income
|
-25.4m
USD
|
Other Expenses
|
-1.9m
USD
|
Net Income
|
-27.3m
USD
|
Free Cash Flow Analysis
Eyenovia Inc
What is Free Cash Flow?
EYEN Profitability Score
Profitability Due Diligence
Eyenovia Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Eyenovia Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
EYEN Solvency Score
Solvency Due Diligence
Eyenovia Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Eyenovia Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EYEN Price Targets Summary
Eyenovia Inc
According to Wall Street analysts, the average 1-year price target for EYEN is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.
Ownership
EYEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EYEN Price
Eyenovia Inc
Average Annual Return | -18.94% |
Standard Deviation of Annual Returns | 44.71% |
Max Drawdown | -87% |
Market Capitalization | 44.9m USD |
Shares Outstanding | 44 122 200 |
Percentage of Shares Shorted | 7.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2018-01-25. The firm is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The firm is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The firm's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).
Contact
IPO
Employees
Officers
The intrinsic value of one EYEN stock under the Base Case scenario is 4.062 USD.
Compared to the current market price of 0.986 USD, Eyenovia Inc is Undervalued by 76%.